Is PROCEPT BioRobotics Stock Worth Holding?

January 13. 2023. 6 mins read

We don’t have to tell our readers that it’s been tough to find many, if any, feel-good stories in the tech market. Based on our risk-averse approach to disruptive tech investing, we’ve been able to stave off the kind of losses more aggressive funds have experienced over the last year. That’s largely because we’ve developed – and continue to tweak – an objective methodology to why and when we invest in a company. 

Revisiting the Simple Valuation Ratio

One metric that we often mention regarding timing is our patent-pending simple valuation ratio. The math is simple enough for an MBA to understand: divide market cap by annualized revenues. The resulting number – lower equals better – is a rough guideline as to how cheap or expensive a stock is based on the size of a company versus its revenue. A $1 billion company with $50 million in revenue is a better value (20) than a $10 billion company with $100 million in revenue (100), even if the latter is bigger on paper and pulling in more money overall. This guideline helps us avoid overpaying for a company no matter how great it looks on the outside.

We originally capped the number at 40, which meant we wouldn’t touch a stock with a ratio higher than that. It was somewhat arbitrary and worked well in a bull market where tech companies were rapidly growing both revenue and market cap. However, last year, many of those tech stocks started trading at bargain prices – many at single-digit ratios – with strong growth but significantly smaller market caps. Here’s a snapshot of the richest tech c

Become a premium member and get access to hundreds of premium articles, reports and additional content.

Nanalyze Premium is your comprehensive guide to investing in disruptive technologies. Read by the top investment banks, management consultancies, VCs, and research houses. Trusted by over 100,000 institutional and retail investors. Covering disruptive technologies for over 18 years.